GSK Raises 2025 Sales Profit Forecasts on Specialty Medicines Growth

GSK has raised its profit and sales forecasts for 2025, expecting turnover growth of 6-7% and core earnings per share growth of 10-12%, up from previous guidance. The company reported a strong third quarter with turnover of £8.5 billion, driven by a 16% increase in specialty medicines sales and a 13% rise in shingles vaccine sales. Despite concerns over US and European tariffs, GSK remains confident, citing mitigation plans and ongoing investment, including a $30 billion plan to boost US research and manufacturing. CEO Emma Walmsley highlighted the firm's progress in R&D with four FDA product approvals in 2025 and emphasized positioning for long-term growth. The upcoming leadership transition to Luke Miels in 2026 will focus on navigating trade tariffs, pricing pressures, and expanding new medicines to offset patent expirations. Analysts note that GSK aims for over £40 billion in annual revenues by 2031, with current sales around £34 billion.